Clinical trial site organization consolidation continues with the recent news that a specialized investment bank focusing on healthcare transactions known as Provident Healthcare Partners (Provident) advises an acquisition involving the sale of ForCare Clinical Research to consolidator CenExcel. CenExel has acquired ForCare Clinical Research ("FCR"), an independent dermatology-focused clinical research site conducting Phase 2, 3, and late Phase 1 studies in both clinical and acute conditions on behalf of pharmaceutical and biotech sponsors or their contract research organizations (CROs). ForeCare Clinical Research has additional experience working in rheumatology, neurology, immunology, inflammatory disease, and internal medicine-based studies. CenExel has continued to make trial site organization acquisitions in its quest to build "Centers of Excellence" in various therapeutic realms across America. Most recently, its investor, Webster Equity Partners, announced its intention to sell CenExel. In this case, the strategy has led to increasing asset valuation for the investors and a time for liquidity events.
Will the Clinical Research Site Market be Consolidated?
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).